CLINICAL TRIALS PROFILE FOR RABIES IMMUNE GLOBULIN (HUMAN)

All Clinical Trials for rabies immune globulin (human)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02040090 ↗	Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects	Completed	Kamada, Ltd.	Phase 2/Phase 3	2013-04-01	The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether KamRAB interferes with the development of self active antibodies when given simultaneously with active rabies vaccine, as compared to the HRIG comparator product, also given in conjunction with the active rabies vaccine.
NCT02564471 ↗	Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.	Completed	Kansas State University	Phase 4	2016-11-11	This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
NCT02564471 ↗	Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.	Completed	Walter Reed Army Institute of Research (WRAIR)	Phase 4	2016-11-11	This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.
NCT02564471 ↗	Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.	Completed	State University of New York - Upstate Medical University	Phase 4	2016-11-11	This is an exploratory trial to evaluate the effect of antimalarial drugs on the immune response generated by rabies vaccine when administered for post-exposure prophylaxis. This study will use the FDA approved post-exposure prophylaxis vaccine regimen (without rabies immune globulin) in the presence or absence of an FDA-approved malaria chemoprophylaxis regimen.

Clinical Trial Conditions for rabies immune globulin (human)

Condition Name

Condition Name for rabies immune globulin (human)
Intervention	Trials
Rabies	2

Condition MeSH

Condition MeSH for rabies immune globulin (human)
Intervention	Trials
Rabies	2

Clinical Trial Locations for rabies immune globulin (human)

Trials by Country

Trials by Country for rabies immune globulin (human)
Location	Trials
United States	2

Trials by US State

Trials by US State for rabies immune globulin (human)
Location	Trials
New York	1
Minnesota	1

Clinical Trial Progress for rabies immune globulin (human)

Clinical Trial Phase

Clinical Trial Phase for rabies immune globulin (human)
Clinical Trial Phase	Trials
Phase 4	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for rabies immune globulin (human)
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for rabies immune globulin (human)

Sponsor Name

Sponsor Name for rabies immune globulin (human)
Sponsor	Trials
Kamada, Ltd.	1
Kansas State University	1
Walter Reed Army Institute of Research (WRAIR)	1

Sponsor Type

Sponsor Type for rabies immune globulin (human)
Sponsor	Trials
Other	2
U.S. Fed	1
Industry	1